Compare LEU & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEU | AMRX |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.0B |
| IPO Year | 1998 | N/A |
| Metric | LEU | AMRX |
|---|---|---|
| Price | $196.76 | $14.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $232.92 | $13.25 |
| AVG Volume (30 Days) | 1.5M | ★ 3.8M |
| Earning Date | 02-10-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.90 | 0.02 |
| Revenue | $448,700,000.00 | ★ $2,934,959,000.00 |
| Revenue This Year | $8.58 | $9.99 |
| Revenue Next Year | $3.99 | $6.48 |
| P/E Ratio | ★ $51.07 | $789.64 |
| Revenue Growth | 1.52 | ★ 9.50 |
| 52 Week Low | $49.40 | $6.69 |
| 52 Week High | $464.25 | $15.00 |
| Indicator | LEU | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.89 | 67.23 |
| Support Level | $230.51 | $14.55 |
| Resistance Level | $276.89 | $14.99 |
| Average True Range (ATR) | 29.50 | 0.48 |
| MACD | -11.80 | 0.01 |
| Stochastic Oscillator | 1.82 | 78.84 |
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.